Elastin peptides are protein fragments derived from elastin, an extracellular-matrix protein involved in tissue stretch and recoil, and human research has mainly examined oral or topical elastin-derived ingredients for skin measures, vascular-function context, and endogenous elastin-fragment biomarkers. (Review)
Elastin peptides are distinct from collagen peptides because elastin and collagen serve different structural roles in connective tissue. (Review) Human intervention evidence for elastin peptides is currently narrowest but clearest in Beauty and Skin Health, especially a randomized trial of oral bonito-derived elastin peptide and small topical studies of elastin-derived or elastin-like peptides. (Research) Broader human literature on elastin-derived peptides mostly measures endogenous elastin fragments as biomarkers in vascular, lung, metabolic, autoimmune, and aging-related contexts rather than testing oral supplementation. (Review)
Ingredient Identity
- Official name(s): Elastin peptides; elastin hydrolysate; elastin-derived peptides. (Review)
- Synonyms: Elastin hydrolysate, elastin peptide hydrolysate, soluble elastin peptides, elastin-derived peptides, EDPs, kappa-elastin, elastokines. (Review)
- Classification: Protein hydrolysate / extracellular-matrix-derived peptide category. (Review)
- CAS number: No single CAS number applies to elastin peptide mixtures because these ingredients vary by source species, hydrolysis method, molecular-weight distribution, and peptide profile. (Research)
- Endogenous vs exogenous: Elastin-derived peptides can form endogenously during elastin degradation, and exogenous elastin peptides can be produced by hydrolyzing elastin-rich animal tissues for research or ingredient use. (Review)
Ingredient Snapshot
- Classification: Elastin peptides are extracellular-matrix-derived protein fragments produced from elastin or elastin-like sequences. (Review)
- Endogenous vs exogenous status: Endogenous elastin-derived peptides are released during elastin breakdown, while exogenous oral ingredients have been studied as hydrolyzed fish or porcine elastin peptides. (Review) (Research)
- Primary human research domains: Human studies most directly examine Beauty and Skin Health, with smaller or less direct evidence in Cardiovascular Health, Joint Health, Respiratory and Lung Health, Diabetes and Glycemic Control, Autoimmune Disorders, and Aging and Longevity Research. (Research) (Review)
- Common study formats: The evidence includes randomized oral skin trials, topical split-face cosmetic studies, acute absorption studies, trial registrations, and observational biomarker studies. (Research) (Research) (Research)
- Pharmacokinetic characterization status: Human pharmacokinetic characterization is limited, but one human absorption study detected Pro-Gly in blood after elastin hydrolysate ingestion and reported a peak at 30 minutes. (Research)
- Regulatory context (U.S./EU): FDA provides a general GRAS framework for substances intentionally added to food, but this review did not identify an elastin-peptide-specific FDA GRAS notice. (FDA) (FDA)
- Regulatory context (EU): EFSA assessed egg membrane hydrolysate, a related matrix containing elastin, collagen, and glycosaminoglycans, as safe at 450 mg/day for adult food-supplement use, but this is not a purified elastin-peptide assessment. (EFSA)
- Evidence maturity: Overall human evidence is Limited / Mixed, with the clearest direct intervention evidence in oral and topical skin studies and broader but non-supplemental biomarker evidence in vascular and disease contexts. (Research) (Review)
Introduction
Elastin is a connective-tissue protein that helps elastic tissues stretch and recoil, and elastin peptides are smaller fragments derived from elastin through enzymatic breakdown, hydrolysis, or experimental elastin-like sequence design. (Review) Elastin occurs naturally in tissues such as skin, blood vessels, and lungs, while studied oral elastin peptide ingredients have been sourced from elastin-rich animal tissues such as bonito fish arterial bulb and porcine aorta. (Research) (Research)
People often look up elastin peptides because elastin is associated with skin elasticity, vascular elasticity, and extracellular-matrix remodeling. (Review) Human research has examined oral elastin peptides for skin hydration and wrinkle-related outcomes, topical elastin-derived peptides for skin remodeling markers, and endogenous elastin-derived peptides as biomarkers in vascular, lung, metabolic, and autoimmune conditions. (Research) (Research) (Review)
This article is informational only, describes elastin peptides as biochemical substances studied in human research, and does not provide medical or dosing advice.
Quick Summary
- Elastin peptides are elastin-derived protein fragments studied as oral hydrolysates, topical elastin-derived peptides, and endogenous elastin-fragment biomarkers. (Review)
- The clearest direct human evidence is in Beauty and Skin Health, where a 12-week RCT found that 100 mg/day oral bonito elastin peptide improved several objective wrinkle, hydration, and melanin-index measures versus placebo. (Research)
- Topical elastin-derived peptide evidence exists, but it is based on small short-term studies such as 28-day split-face trials of a trifunctional elastin-derived peptide cream. (Research)
- Human oral evidence for Cardiovascular Health and Joint Health is much less mature than skin evidence, and accessible high-trust trial publications are limited. (Review)
- Endogenous elastin-derived peptides are widely studied as biomarkers and signaling fragments in vascular, lung, metabolic, autoimmune, and aging-related contexts, but biomarker evidence is not the same as oral supplement efficacy evidence. (Review)
- Elastin peptides differ from collagen peptides because elastin is linked to elastic recoil and resilience, while collagen is more closely associated with tensile strength and structural scaffolding. (Review)
- Collagen peptides have broader clinical supplementation evidence than elastin peptides, including meta-analyses of randomized trials for skin hydration and elasticity. (Review)
Human Research Findings by Condition
Beauty and Skin Health
Human research on Beauty and Skin Health includes oral elastin peptide trials, topical elastin-derived peptide studies, and topical elastin-like recombinant polypeptide research. (Research) The strongest direct oral evidence is a randomized placebo-controlled trial using bonito-derived elastin peptide, while topical evidence remains smaller and shorter in duration. (Research)
Key human study
Dose studied: 100 mg/day oral bonito fish-derived elastin peptide
Population: 100 healthy Korean adults aged 35–60 with visible crow’s-feet wrinkles and low cheek hydration
Duration: 12 weeks
Researchers randomized participants to a capsule containing 100 mg/day bonito elastin peptide or placebo and measured skin wrinkles, hydration, melanin index, erythema index, and safety labs at baseline and follow-up visits. (Research) The study reported greater improvement in several PRIMOS wrinkle parameters, skin hydration, and melanin index in the elastin peptide group than in the placebo group after 12 weeks. (Research)
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
Additional human study
Dose studied: 100 mg/day and 200 mg/day oral porcine elastin peptide
Population: 39 middle-aged volunteers in the skin-elasticity intervention component
Duration: 8 weeks
This Japanese human study evaluated porcine elastin peptide ingestion and reported increased skin elasticity in the 100 mg/day and 200 mg/day groups after 8 weeks. (Research) The same publication also reported acute blood increases in peptide-form hydroxyproline and arginine after elastin peptide ingestion in fasting volunteers. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Additional topical human study
Dose studied: 100 µg/mL topical trifunctional elastin-derived peptide cream, applied twice daily
Population: 22 women aged 45–70 in a split-face study before surgical lifting
Duration: 28 days
This topical study tested a trifunctional elastin-derived peptide cream on one hemi-face and placebo cream on the other hemi-face. (Research) The study reported improved firmness and wrinkle-depth measures and examined extracellular-matrix remodeling markers in skin tissue. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Emerging
Study source: (Research)
Cardiovascular Health
Human research in Cardiovascular Health is stronger for endogenous elastin-derived peptide biomarkers than for oral elastin peptide supplementation. (Review) Reviews describe elastin-derived peptides as bioactive fragments that can retain VGVAPG-related signaling capability and have been studied in vascular disease contexts, but this evidence should not be converted into oral supplement claims. (Review)
Key human study
Dose studied: Endogenous serum elastin peptide measurement, not supplementation
Population: Patients with small abdominal aortic aneurysms
Duration: Follow-up context
Researchers studied serum elastin peptides as possible predictors of small abdominal aortic aneurysm expansion. (Research) This type of study evaluates elastin peptide levels as vascular biomarkers and does not test whether oral elastin peptide intake changes aneurysm risk or vascular outcomes. (Research)
Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)
Additional human study
Dose studied: Endogenous serum elastin peptide measurement, not supplementation
Population: Abdominal aortic aneurysm patients
Duration: Clinical assessment context
A separate human study measured serum elastin peptides, elastin–alpha1-antitrypsin complexes, and collagen metabolism markers in relation to abdominal aortic aneurysm distensibility. (Research) The study supports the relevance of elastin turnover to vascular structure, but it does not provide evidence that oral elastin peptides improve cardiovascular outcomes. (Research)
Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)
Joint Health
Human evidence in Joint Health is limited and mainly comes from small or registry-level elastin peptide studies rather than large peer-reviewed clinical trials. (Research) Because elastin is present in elastic connective tissues but joint-symptom research is sparse, findings should be framed as preliminary and not compared with the larger collagen peptide literature. (Review)
Key human study
Dose studied: Two capsules/day of a supplement containing horse-derived elastin peptides
Population: Healthy Japanese adults aged 40 to under 75 with knee-related eligibility criteria
Duration: 12 weeks
A UMIN-registered randomized, double-blind, placebo-controlled trial listed horse-derived elastin peptides as the intervention and included JKOM and JOA knee-related outcomes. (Research) The registry supports the existence and design of the study, but registry information should not be interpreted as completed efficacy evidence unless peer-reviewed results are available. (Research)
Result: Human evidence remains limited or inconclusive
Evidence strength: Emerging
Study source: (Research)
Additional context
Dose studied: 75 mg/day bonito elastin peptide with or without 1,000 mg/day glucosamine in a small source-reported study
Population: Japanese adults with self-reported knee discomfort
Duration: 12 weeks
A source summary described a small study of bonito elastin peptide alone and in combination with glucosamine for knee-discomfort outcomes. (Research) Because this source is not a high-trust peer-reviewed trial record, it should be used cautiously or omitted from stronger evidence claims. (Research)
Result: Human evidence remains limited or inconclusive
Evidence strength: Limited
Study source: (Research)
Respiratory and Lung Health
Human studies in Respiratory and Lung Health primarily measure endogenous elastin-derived peptides as extracellular-matrix turnover markers rather than testing oral or topical elastin peptide interventions. (Research) Findings across lung biomarker studies are mixed, with some studies suggesting relationships to emphysema-related measures and others reporting weak or absent serum-marker relationships. (Research)
Key human study
Dose studied: Endogenous elastin peptide measurement in plasma, urine, and bronchoalveolar lavage fluid
Population: Healthy volunteers, smokers, and COPD patients
Duration: Cross-sectional fluid-comparison study
Researchers measured elastin peptide concentrations across body fluids to examine extracellular-matrix turnover in respiratory contexts. (Research) This study supports elastin-derived peptides as respiratory biomarkers, but it does not test oral elastin peptide supplementation. (Research)
Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)
Additional human study
Dose studied: Endogenous serum elastin peptide measurement, not supplementation
Population: Male emphysema patients and male worker control cohorts
Duration: Cross-sectional comparison
This study compared serum elastin peptide levels in emphysema patients and controls and explored relationships with high-resolution CT emphysema scores. (Research) The study reported no clear difference in serum elastin peptide levels between emphysema patients and controls, which illustrates mixed evidence for serum elastin peptides as respiratory biomarkers. (Research)
Result: Human clinical study reported no clear effect
Evidence strength: Mixed
Study source: (Research)
Diabetes and Glycemic Control
Human evidence in Diabetes and Glycemic Control concerns glycated elastin-derived peptides and vascular complications, not oral elastin peptide supplementation. (Research) Non-human studies have tested oral bonito-derived elastin peptides in hypertensive rat models with glucose-intolerance features, but those findings remain experimental. (Research)
Key human study
Dose studied: Serum glycated elastin-derived peptide measurement, not supplementation
Population: Patients with type 2 diabetes and arterial hypertension
Duration: Cross-sectional clinical biomarker study
Researchers measured glycated elastin-derived peptides in patients with type 2 diabetes and arterial hypertension to examine links with metabolic and vascular complications. (Research) This supports a disease-biomarker role for elastin-derived peptides, but it does not show that oral elastin peptide intake improves glycemic control. (Research)
Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)
Autoimmune Disorders
Human evidence in Autoimmune Disorders is limited to elastin-derived peptide and anti-elastin antibody measurements in systemic sclerosis and related immune contexts. (Research) These studies evaluate immune and extracellular-matrix markers rather than elastin peptide ingestion or topical use. (Research)
Key human study
Dose studied: Serum elastin-derived peptide and anti-elastin antibody measurement, not supplementation
Population: Patients with systemic sclerosis
Duration: Cross-sectional clinical assessment
Researchers investigated relationships between systemic sclerosis manifestations and serum levels of soluble elastin-derived peptides and anti-elastin antibodies. (Research) The study reported associations between serum elastin-derived peptide concentration and disease duration in some analyses, but it did not test elastin peptides as an intervention. (Research)
Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)
Aging and Longevity Research
Human research in Aging and Longevity Research is mainly indirect because elastin turnover changes with age and elastin-derived peptides are studied as markers or mediators of tissue remodeling. (Review) Skin aging is the most direct intervention area, while vascular aging evidence is mostly biomarker or mechanistic. (Research) (Review)
Key human study
Dose studied: 100 mg/day oral bonito elastin peptide
Population: Healthy Korean adults with visible wrinkle and hydration inclusion criteria
Duration: 12 weeks
The skin RCT measured aging-related skin appearance and biophysical parameters such as wrinkle roughness, skin hydration, and melanin index. (Research) The study supports short-term skin-aging context but does not establish broader longevity effects. (Research)
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate for skin-aging measures; limited for broader aging claims
Study source: (Research)
Dosage & Study Snapshot (Research Context)
Human elastin peptide exposure has been studied through topical concentrations, oral daily milligram doses, and one acute gram-level absorption study. (Research) The oral intervention literature is narrower than common supplement-market dose ranges, and no adequately verified chronic human safety study was identified for 1,600–3,000 mg/day oral elastin peptide intake. (Research) The dose bands below describe research contexts only and are not dosing advice.
100 µg/mL topical TFP, twice daily:
A topical trifunctional elastin-derived peptide cream at 100 µg/mL was applied twice daily in 28-day split-face studies. (Research) The clinical validation study included 22 women aged 45–70 and compared TFP cream with placebo cream on opposite hemi-faces. (Research) A later study used the same concentration and twice-daily approach in 24 women while examining glycated vimentin, NRF2, autophagy, and skin-regeneration biology. (Research) This topical exposure is not comparable to oral milligram intake because it is applied locally to skin rather than ingested. (Research)
Result: Modest improvement
Evidence strength: Emerging
Notes / limitations: Topical evidence is short-term and based on small cosmetic studies.
75 mg/day oral bonito-derived elastin peptide:
A 75 mg/day oral bonito-derived elastin peptide exposure appears in Japanese functional-food and source-reported contexts for vascular and knee-related outcomes. (Research) The available high-trust evidence base for this dose is weaker than for the 100 mg/day bonito skin RCT because the most accessible vascular and knee reports are not widely indexed primary clinical publications. (Review) The dose may be relevant for article context but should not be presented as a strongly established human dose. (Research)
Result: Inconclusive
Evidence strength: Limited
Notes / limitations: Use cautious wording because source quality and independent replication are limited.
100 mg/day oral bonito fish-derived elastin peptide:
A randomized, double-blind, placebo-controlled trial used 100 mg/day bonito fish-derived elastin peptide in capsule form for 12 weeks. (Research) The study population included 100 healthy Korean adults, and outcomes included objective wrinkle measures, skin hydration, melanin index, erythema index, and laboratory safety measures. (Research) The trial reported improvements in several wrinkle parameters, skin hydration, and melanin index compared with placebo. (Research) This dose is the strongest direct oral elastin-peptide dose band for Beauty and Skin Health in the current evidence set. (Research)
Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: The study tested one specific bonito-derived ingredient and does not automatically generalize to all elastin peptide sources.
100–200 mg/day oral porcine elastin peptide:
A Japanese human study tested 100 mg/day and 200 mg/day porcine elastin peptide for 8 weeks in a skin-elasticity intervention. (Research) The study reported increased skin elasticity in the elastin peptide groups, with both active-dose groups showing improvement. (Research) The same article also included an acute absorption component measuring peptide-form hydroxyproline and arginine in blood after ingestion. (Research) This dose band is useful for source diversity because it involves porcine rather than fish elastin peptide. (Research)
Result: Modest improvement
Evidence strength: Limited
Notes / limitations: The publication is less accessible internationally than the bonito RCT, and study size was smaller.
50 mL/day multi-ingredient peptide beverage containing elastin peptide:
An 8-week randomized controlled trial used a 50 mL/day beverage containing collagen tripeptide, fish collagen peptides, bonito elastin peptide powder, and salmon nasal cartilage compound powder. (Research) The study reported improvements in skin hydration, transepidermal water loss, elasticity, dermal collagen content, pores, wrinkle length, smoothness, and roughness. (Research) This evidence does not isolate the elastin peptide contribution because the product included several active matrix-derived ingredients. (Research) This band is best interpreted as combination-formulation evidence rather than elastin-peptide-only evidence. (Research)
Result: Modest improvement
Evidence strength: Limited
Notes / limitations: The elastin-specific dose and independent effect cannot be separated from the multi-ingredient formulation.
10 g/60 kg body weight acute oral elastin hydrolysate:
A human absorption study administered 10 g/60 kg body weight elastin hydrolysate and measured food-derived peptides in blood. (Research) Pro-Gly was identified as the major food-derived elastin peptide and reached a maximum of 18 µM at 30 minutes after ingestion. (Research) Pro-Gly decreased to about 20% of peak concentration by 4 hours after ingestion. (Research) This acute gram-level exposure supports absorption characterization but does not establish chronic daily safety at gram-level doses. (Research)
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: This was an acute absorption study rather than a chronic efficacy or safety trial.
Key Takeaways from Human Research
- The strongest direct human evidence for elastin peptides is in Beauty and Skin Health, where 100 mg/day oral bonito elastin peptide improved several objective skin measures in a 12-week RCT. (Research)
- Topical elastin-derived peptide evidence is promising but early, with small 28-day studies using 100 µg/mL TFP cream in split-face or tissue-linked designs. (Research) (Research)
- Human absorption evidence shows that Pro-Gly can appear in blood after elastin hydrolysate ingestion, but pharmacokinetic characterization remains limited. (Research)
- Vascular and lung research often measures endogenous elastin-derived peptides as biomarkers, which should not be presented as evidence that oral elastin peptide supplementation improves those conditions. (Review)
- Elastin peptides differ from collagen peptides in parent protein, tissue role, peptide profile, and evidence maturity. (Review) (Review)
- Long-term safety evidence at high oral intakes such as 1,600–3,000 mg/day was not identified in the verified human elastin-peptide evidence base. (Research)
Origin & Natural Occurrence
Elastin is naturally present in elastic connective tissues, including skin, lungs, and large blood vessels. (Review) Elastin-derived peptides can form endogenously when elastin is degraded by elastases and related proteases during normal remodeling or disease-associated extracellular-matrix breakdown. (Review)
Commercial oral elastin peptide ingredients have been studied from animal sources such as bonito fish and porcine aorta. (Research) (Research) The 2024 oral RCT used bonito fish-derived elastin peptide from Katsuwonus pelamis with an average molecular weight of 582 Da. (Research)
Egg membrane hydrolysate is related but not identical to purified elastin peptides because EFSA describes it as a matrix containing elastin, collagen, and glycosaminoglycans. (EFSA) Salmon-derived materials are more commonly discussed in collagen or cartilage contexts in the reviewed evidence, and no strong salmon-specific human elastin-peptide ingestion study was identified in this evidence set. (Research)
How It Behaves in the Body
In plain terms, oral elastin peptides are broken down into smaller peptides and amino-acid-containing fragments, and at least some elastin-derived peptides can appear in the blood after ingestion. (Research) The clearest human absorption marker in the verified evidence is Pro-Gly, which peaked in blood 30 minutes after an acute elastin hydrolysate dose and declined substantially by 4 hours. (Research)
Mechanistically, elastin-derived peptides may interact with elastin-related receptor pathways, especially sequences containing VGVAPG-like motifs. (Review) Reviews describe elastin-derived peptides as bioactive fragments that can participate in cell signaling, inflammatory responses, vascular remodeling, and extracellular-matrix turnover. (Review)
Topical elastin-derived peptides behave differently from oral peptides because they are applied locally to skin and studied for surface or dermal remodeling outcomes rather than systemic absorption. (Research) The topical TFP studies examined extracellular-matrix remodeling markers, glycated vimentin degradation, NRF2 activation, and autophagy-related pathways in skin-linked systems. (Research)
What is well established is that elastin is a structural extracellular-matrix protein involved in elasticity and recoil. (Review) What remains less established is whether different oral elastin peptide sources, peptide profiles, and doses produce consistent human effects beyond short-term skin measures. (Research)
Absorption & Delivery Formats
Oral immediate-release: Oral elastin peptide capsules and hydrolysates have been studied in humans, including a 100 mg/day bonito-derived capsule trial and an acute 10 g/60 kg body weight absorption study. (Research) (Research)
Oral extended-release: No verified human extended-release elastin peptide study was identified in the current evidence set. (Research)
Sublingual: No verified human sublingual elastin peptide pharmacokinetic or clinical study was identified in the current evidence set. (Research)
Transdermal / topical: Topical elastin-derived peptides have been studied in small human cosmetic studies, including twice-daily TFP cream at 100 µg/mL for 28 days. (Research) Topical evidence should be separated from oral evidence because local skin application does not imply systemic absorption or oral effects. (Research)
Injectable / IV: Injectable or IV elastin peptide use is not established as a supplement delivery format in the verified human evidence. (Review) Animal injection studies of elastin-derived peptides are mechanistic and should not be treated as supplement-use evidence. (Research)
Quick Facts at a Glance
Onset (reported)
The clearest human absorption onset data come from the acute elastin hydrolysate study, where Pro-Gly appeared in blood and peaked by 30 minutes after ingestion. (Research) The clearest human skin-effect timing comes from the 12-week oral bonito trial, where assessments occurred at 4, 8, and 12 weeks. (Research)
Time to peak (Tmax)
Pro-Gly reached its reported maximum concentration at 30 minutes after ingestion of 10 g/60 kg body weight elastin hydrolysate. (Research) Tmax has not been comprehensively characterized across different commercial elastin peptide sources, molecular weights, or oral doses. (Research)
Half-life (t½)
A formal human half-life for elastin peptide mixtures was not identified in the verified evidence. (Research) The absorption study reported that Pro-Gly decreased to about 20% of peak by 4 hours, but this decline should not be treated as a validated half-life for all elastin-derived peptides. (Research)
Typical duration
Oral human intervention studies identified in this evidence set used durations such as 8 weeks and 12 weeks for skin-related outcomes. (Research) (Research) Topical TFP studies used 28-day application periods. (Research)
Absorption routes studied
Oral absorption has been studied through blood detection of Pro-Gly after elastin hydrolysate ingestion. (Research) Topical delivery has been studied through local skin application and skin-tissue outcomes rather than systemic pharmacokinetics. (Research)
Formulation differences
Human oral studies differ by source species, including bonito fish-derived and porcine aorta-derived elastin peptide ingredients. (Research) (Research) Topical studies use designed elastin-derived or elastin-like polypeptides rather than the same hydrolyzed oral ingredients. (Research)
Variability drivers
Likely variability drivers include source species, tissue source, hydrolysis process, molecular-weight distribution, peptide sequence profile, and delivery route. (Research) The 2024 oral RCT reported an average molecular weight of 582 Da for its bonito-derived elastin peptide, which may not apply to other elastin peptide products. (Research)
Tolerance / adaptation
No clear human tolerance or adaptation pattern was identified for oral elastin peptides in the verified evidence. (Research) The 12-week bonito trial reported no test-product-related adverse events, but this does not establish tolerance behavior across higher doses, longer use, or different source materials. (Research)
Evidence strength snapshot
Evidence is strongest for short-term Beauty and Skin Health outcomes using one specific oral bonito-derived elastin peptide ingredient and small topical peptide studies. (Research) Evidence is weaker for oral vascular, joint, metabolic, lung, autoimmune, and aging outcomes because much of that literature is biomarker, registry, source-summary, or non-human evidence. (Review)
Other Physiological Contexts Studied (If Applicable)
- Non-human vascular research found that oral bonito bulbus arteriosus-derived elastin peptide at 1 g/kg body weight for 5 weeks affected vascular dysfunction markers in spontaneously hypertensive rats. (Research)
- A 2026 rat study reported that bonito-derived elastin peptides improved glucose tolerance and renal vascular markers in stroke-prone spontaneously hypertensive rats, but this does not establish human glycemic-control effects. (Research)
- Mouse atherosclerosis research found that chronic injected elastin-derived peptides or VGVAPG exposure increased plaque formation through immune Neu1–PI3Kγ signaling, showing that elastin-fragment signaling can be unfavorable in some disease models. (Research)
- Rat aortic-ring studies reported endothelium-dependent vascular relaxation after exposure to kappa-elastin, but isolated-tissue findings do not establish oral supplement effects in humans. (Research)
- Skin-model research using UVB-irradiated human skin cells and hairless mice found that bonito Elastin HC affected hydration-, wrinkle-, and pigmentation-related markers. (Research)
- Human fibroblast and cell-culture work supports mechanistic plausibility for elastin-derived peptides, but in vitro findings should not be described as clinical efficacy. (Research)
Safety, Interactions & Regulation
The 12-week oral bonito elastin peptide RCT reported no adverse effects related to the test product and found blood and urine analyses within normal ranges. (Research) This safety evidence applies to the studied product and dose, 100 mg/day, and does not establish chronic safety at gram-level daily intakes such as 1,600–3,000 mg/day. (Research)
Topical TFP studies provide short-term topical-use context, but their sample sizes and 28-day durations limit broad safety conclusions. (Research) Source-related considerations may differ for fish, porcine, equine, bovine, or egg-derived materials because allergen, religious, dietary, contaminant, and manufacturing issues vary by source material. (EFSA)
No well-characterized human drug-interaction literature was identified for oral elastin peptide supplements. (Research) Registry-based horse-derived elastin peptide trials excluded groups such as people with major medical conditions, pregnancy or lactation, medication or supplement use, and allergy to horse-derived substances, which limits generalizability. (Research)
In the United States, FDA explains that substances intentionally added to food are generally food additives requiring premarket approval unless they are GRAS or otherwise excluded from the food-additive definition. (FDA) FDA’s GRAS Notice Inventory is the official inventory of GRAS notices filed since 1998, and this review did not identify an elastin-peptide-specific notice in that inventory. (FDA)
In the European Union, EFSA assessed egg membrane hydrolysate as a novel food and described its main constituents as elastin, collagen, and glycosaminoglycans. (EFSA) EFSA concluded that egg membrane hydrolysate was safe as a food supplement at 450 mg/day for adults under the proposed conditions, but this assessment should not be generalized to purified fish, porcine, equine, or bovine elastin peptide ingredients. (EFSA) Commission Implementing Regulation (EU) 2026/1427 authorized enzymatically produced egg membrane hydrolysate at levels not exceeding 500 mg/day for food supplements in the general adult population, excluding pregnant and lactating women. (EFSA)
Evidence Overview
The overall human evidence for elastin peptides is narrow and formulation-specific, with the clearest direct intervention findings in Beauty and Skin Health and much weaker direct evidence for other health areas. (Research) Oral skin evidence includes a 12-week randomized trial of 100 mg/day bonito elastin peptide and an 8-week Japanese porcine elastin peptide study, while topical skin evidence includes small 28-day studies of designed elastin-derived peptides. (Research) (Research) (Research) Confidence is not higher because the evidence base contains few large independent trials, short durations, different source materials, and many studies that examine biomarkers rather than supplementation. (Review)
The most important evidence distinction is between exogenous elastin peptide interventions and endogenous elastin-derived peptide biomarkers. (Review) Human biomarker studies show that elastin-derived peptides are relevant to extracellular-matrix turnover in abdominal aortic aneurysm, lung disease, diabetes with hypertension, systemic sclerosis, and vascular aging contexts. (Research) (Research) (Research) These studies do not establish that taking oral elastin peptides improves those conditions. (Review)
Mechanistic evidence is biologically interesting but context-dependent. (Review) Some non-human studies report vascular or metabolic-marker changes after oral elastin peptide exposure, while other disease-model studies suggest that elastin-derived peptide signaling can promote atherosclerosis-related processes under certain conditions. (Research) (Research) This mixed mechanistic picture supports cautious language rather than broad benefit claims. (Review)
Elastin peptides should also be distinguished from collagen peptides. (Review) Collagen peptide supplementation has broader human evidence, including systematic reviews and meta-analyses of randomized trials for skin hydration and elasticity, whereas elastin peptide evidence remains smaller and more source-specific. (Review)
Evidence Confidence Classification
Limited / Mixed is the overall human evidence classification for elastin peptides because direct human intervention evidence exists but is concentrated in short-term skin studies, while many other research areas rely on biomarkers, non-human models, or registry-level information. (Research) (Review)
The evidence is moderate for one specific oral bonito elastin peptide skin study, because that trial was randomized, double-blind, placebo-controlled, and included 100 healthy adults. (Research) The evidence remains emerging for topical elastin-derived peptides, because topical studies are small and short-term. (Research) The evidence is observational or mechanistic for vascular, lung, metabolic, autoimmune, and broader aging contexts because those studies mainly measure endogenous elastin-derived peptides or use animal and cell models. (Review)
Similar Ingredients & Comparators
Similar supplement-style ingredients:
- Collagen peptides
- Hydrolyzed collagen
- Collagen tripeptides
- Egg membrane hydrolysate
- Hyaluronic acid
- Chondroitin sulfate
- Glucosamine
- Keratin peptides
- Silk peptides
- Marine fish peptides
- Amino-acid peptide complexes
Medical / pharma comparator categories:
- Dermatologic topical retinoid categories
- Cosmetic peptide categories
- Injectable dermal filler categories
- Vascular biomarker categories
- Osteoarthritis symptom-management categories
- Extracellular-matrix remodeling research categories
Combination Context
Elastin peptides + collagen tripeptide:
A randomized human trial tested a beverage containing collagen tripeptide and elastin peptide along with other matrix-derived ingredients. (Research) The study reported skin improvements, but the elastin-specific contribution could not be separated from the full multi-ingredient formula. (Research)
Elastin-containing egg membrane hydrolysate + collagen + glycosaminoglycans:
EFSA describes egg membrane hydrolysate as a matrix whose main constituents include elastin, collagen, and glycosaminoglycans. (EFSA) This is a related matrix ingredient rather than purified elastin peptide, so it should not be used as direct evidence for fish or porcine elastin peptide effects. (EFSA)
Elastin peptides + glucosamine:
A small source-reported Japanese study described bonito elastin peptide with glucosamine for knee-discomfort outcomes. (Research) This combination should be treated as low-confidence context because the accessible source is not a high-trust peer-reviewed clinical publication. (Research)
FAQ
What are elastin peptides?
Elastin peptides are smaller protein fragments derived from elastin, a connective-tissue protein involved in elastic recoil and resilience. (Review) They can occur endogenously when elastin breaks down in tissues, or they can be produced exogenously by hydrolyzing elastin-rich animal materials. (Review) Human supplement research mainly studies oral elastin hydrolysates, while topical research studies elastin-derived or elastin-like designed peptides. (Research)
What does human research study elastin peptides for?
Human research studies elastin peptides most directly for Beauty and Skin Health, including wrinkles, hydration, elasticity, melanin index, and topical skin-remodeling markers. (Research) Human biomarker research also studies endogenous elastin-derived peptides in vascular, lung, metabolic, autoimmune, and aging-related contexts. (Review) These biomarker studies do not prove oral supplement effects. (Review)
What are the best-supported uses?
The best-supported direct human research area is Beauty and Skin Health, especially the 12-week RCT of 100 mg/day oral bonito elastin peptide. (Research) Topical elastin-derived peptide studies also report short-term skin-firmness and wrinkle-depth outcomes, but their evidence base is smaller. (Research) Other areas should be described as limited, observational, or mechanistic. (Review)
Where is evidence mixed or limited?
Evidence is mixed or limited outside Beauty and Skin Health because many studies measure endogenous elastin-derived peptides rather than testing oral or topical elastin peptide ingredients. (Review) Lung biomarker studies, for example, have produced inconsistent findings for serum elastin peptides in emphysema-related contexts. (Research) Vascular and metabolic evidence includes observational human biomarker studies and non-human experiments rather than robust oral supplement trials. (Research)
How quickly does it act?
The clearest pharmacokinetic signal is that Pro-Gly peaked in blood 30 minutes after acute ingestion of 10 g/60 kg body weight elastin hydrolysate. (Research) Clinical skin outcomes in the oral bonito RCT were assessed over 4, 8, and 12 weeks. (Research) Topical TFP studies used twice-daily application for 28 days. (Research)
What affects absorption and variability?
Absorption and variability likely depend on source species, hydrolysis process, peptide sequence, molecular-weight distribution, and route of administration. (Research) The oral bonito RCT used a fish-derived ingredient with an average molecular weight of 582 Da, while the human absorption study measured Pro-Gly after elastin hydrolysate ingestion. (Research) (Research) Topical elastin-derived peptides should not be assumed to behave like oral hydrolysates. (Research)
Is tolerance reported?
No well-defined tolerance or adaptation pattern was identified for oral elastin peptides in the verified human evidence. (Research) The 12-week oral bonito RCT reported no adverse effects related to the test product, but this does not establish long-term tolerance across other products or higher intakes. (Research) Topical studies provide only short-term tolerability context. (Research)
Why do studies disagree?
Studies differ because they examine different peptide sources, delivery routes, molecular-weight profiles, outcome measures, populations, and durations. (Research) Some studies test oral hydrolysates, while others test topical designed peptides or measure endogenous disease biomarkers. (Research) (Review) Non-human studies also show context-dependent signaling, including both vascular-marker improvements and unfavorable atherosclerosis-related signaling in disease models. (Research) (Research)
What ingredients is it commonly combined with and why?
Elastin peptides have been studied in combination with collagen tripeptide and other matrix-derived ingredients in a skin-focused beverage trial. (Research) Egg membrane hydrolysate is a related matrix ingredient that contains elastin, collagen, and glycosaminoglycans, but it is not purified elastin peptide. (EFSA) Glucosamine has appeared in a small source-reported knee-discomfort combination context, but stronger peer-reviewed evidence is needed before making firm conclusions. (Research)
What foods naturally contain elastin-related material?
Elastin occurs in animal connective tissues such as skin, vessels, and lungs. (Review) The oral bonito elastin peptide RCT used a fish-derived ingredient from Katsuwonus pelamis, and the article noted that participants avoided regular consumption of elastin- or collagen-rich foods such as dried or canned bonito during the study. (Research) Commercial elastin peptide ingredients are typically produced through hydrolysis rather than consumed as purified elastin peptides from ordinary foods. (Research)
How are elastin peptides regulated?
In the United States, an elastin peptide ingredient would need to fit the applicable legal category for its intended use, and FDA explains that substances intentionally added to food generally require approval unless GRAS or otherwise excepted. (FDA) This review did not identify an elastin-peptide-specific FDA GRAS notice in the FDA GRAS Notice Inventory. (FDA) In the European Union, EFSA has assessed egg membrane hydrolysate as a novel food at 450 mg/day, but that assessment applies to egg membrane hydrolysate and not all elastin peptide ingredients. (EFSA)
Resources
Oral consumption of Bonito fish-derived elastin peptide improves biophysical properties in aging skin — Skin Research and Technology / PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC10938029/
Identification of food-derived elastin peptide Pro-Gly in human blood — Journal of Agricultural and Food Chemistry / PubMed — https://pubmed.ncbi.nlm.nih.gov/22548376/
Clinical validation of an elastin-derived trifunctional peptide for skin regeneration — American Journal of Translational Research / PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC10408523/
NRF2-mediated autophagic degradation of glycated vimentin in the skin by an elastin-derived peptide — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC12709349/
An artificially designed elastin-like recombinant polypeptide improves aging skin — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC9827338/
Elastin-derived peptides in physiology and disease — PubMed — https://pubmed.ncbi.nlm.nih.gov/31295577/
Elastin, arterial mechanics, and cardiovascular disease — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC6139627/
Safety of egg membrane hydrolysate as a novel food — EFSA Journal — https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2018.5363
FDA Generally Recognized as Safe overview — FDA — https://www.fda.gov/food/food-ingredients-packaging/generally-recognized-safe-gras
FDA GRAS Notice Inventory — FDA — https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory